ZD4054 (Zibotentan) Phase II Non-Small Cell Lung Cancer Study
The aim of this study is to collect initial efficacy and safety data on the use of a new treatment ZD4054 (Zibotentan) when used in combination with pemetrexed (a standard chemotherapy agent) for the treatment of non-small cell lung cancer compared to treatment with pemetrexed alone
Non Small Cell Lung Cancer|Lung Cancer
DRUG: ZD4054|DRUG: Pemetrexed|DRUG: Placebo
Time to Death, Median time (in days) from randomisation until death using the Kaplan-Meier method (Calculator for survival probability), Patients were followed up for survival every week for the first 3 weeks then every 3 weeks whilst on study medication until the data cut-off (17th January 2010).
Progression-free Survival, Median time (in days) from randomisation until disease progression/death using the Kaplan-Meier method, Tumour assessments for progression were performed at screening, every 3 weeks, Mandatory Tumour Assessment Visit (19 August 2009 Â± 3 days), treatment discontinuation
The aim of this study is to collect initial efficacy and safety data on the use of a new treatment ZD4054 (Zibotentan) when used in combination with pemetrexed (a standard chemotherapy agent) for the treatment of non-small cell lung cancer compared to treatment with pemetrexed alone